GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » ROC %

Enzychem Lifesciences (XKRX:183490) ROC % : -15.16% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Enzychem Lifesciences's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -15.16%.

As of today (2024-12-13), Enzychem Lifesciences's WACC % is 11.60%. Enzychem Lifesciences's ROC % is -16.31% (calculated using TTM income statement data). Enzychem Lifesciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Enzychem Lifesciences ROC % Historical Data

The historical data trend for Enzychem Lifesciences's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences ROC % Chart

Enzychem Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.40 -50.02 -38.19 -20.93 -21.20

Enzychem Lifesciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.53 -16.48 -12.64 -20.04 -15.16

Enzychem Lifesciences ROC % Calculation

Enzychem Lifesciences's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-14356.145 * ( 1 - 4.82% )/( (64429.941 + 64454.008)/ 2 )
=-13664.178811/64441.9745
=-21.20 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=247554.987 - 5096.699 - ( 192855.68 - max(0, 42284.411 - 220312.758+192855.68))
=64429.941

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=211545.507 - 9741.277 - ( 137350.222 - max(0, 14154.097 - 174475.031+137350.222))
=64454.008

Enzychem Lifesciences's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-10696.412 * ( 1 - 0.7% )/( (71394.877 + 68733.539)/ 2 )
=-10621.537116/70064.208
=-15.16 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=195137.604 - 7396.521 - ( 116346.206 - max(0, 11151.3 - 160881.463+116346.206))
=71394.877

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=189321.85 - 4294.293 - ( 116294.018 - max(0, 8785.255 - 156091.832+116294.018))
=68733.539

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzychem Lifesciences  (XKRX:183490) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Enzychem Lifesciences's WACC % is 11.60%. Enzychem Lifesciences's ROC % is -16.31% (calculated using TTM income statement data). Enzychem Lifesciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Enzychem Lifesciences ROC % Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzychem Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences Headlines

No Headlines